Inicio / Gastroenterología / Abstracts de gastroenterología / The effect of a microbial…

The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial

0 / 5 (0 votos)
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial

The Lancet Gastroenterology & Hepatology

Fecha de publicación: 22 de febrero de 2021

DOI: https://doi.org/10.1016/S2468-1253(21)00007-8

Autores: Dina Kao, MD , Karen Wong, MD, Rose Franz, RN, Kyla Cochrane, PhD,Keith Sherriff, MSc,Prof Linda Chui, PhD,Colin Lloyd, BSc, Brandi Roach, RN,Anthony D Bai, MD,Elaine O Petrof, MD, Prof Emma Allen-Vercoe, PhD

Background: Faecal microbiota transplantation (FMT) is highly effective for recurrent Clostridioides difficile infection but has inherent risks. Microbial Ecosystem Therapeutic 2 (MET-2) is an oral encapsulated formulation of 40 lyophilised bacterial species initially isolated from stool of a healthy donor, but subsequently manufactured independently of donors, eliminating potential risks introduced by changes in donor health. The aim of this study was to determine MET-2 activity, safety, and tolerability.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.